C4 Therapeutics

CCCC

Market cap $484M

C4 Therapeutics (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in the upcoming conferences.

WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on May 18, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).

Here is how C4 Therapeutics, Inc. (CCCC) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.37 per share a year ago.

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the first quarter ended March 31, 2026, as well as recent business highlights.

C4 Therapeutics said on Thursday it has entered into a deal ​focused on research and development of ‌a type of cancer drug with Swiss drugmaker Roche that could be worth more ​than $1 billion.

Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted Antibodies C4T to Receive $20 Million Upfront Payment and Eligible to Receive Over $1 Billion in Discovery, Development and Commercial Milestones, in Addition to Future Royalties WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced that it has entered into a new collaboration agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to advance research in the emerging degrader-antibody conjugate (DAC) modality.

Here is how C4 Therapeutics, Inc. (CCCC) and Align Technology (ALGN) have performed compared to their sector so far this year.

Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy